Miram

Mirum Pharmaceuticals is a commercial-stage rare disease biopharmaceutical company focused primarily on liver and other severe rare disorders. The company markets LIVMARLI (maralixibat) for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis, as well as Cholbam and CTEXLI for rare bile acid and metabolic indications. Its late-stage pipeline includes volixibat for cholestatic pruritus in primary sclerosing cholangitis and primary biliary cholangitis, and brelovitug for chronic hepatitis delta virus after the 2026 acquisition of Bluejay Therapeutics. Mirum is also developing MRM-3379, a selective PDE4D inhibitor, for Fragile X syndrome. The company is publicly traded on Nasdaq and is headquartered in Foster City, California.